ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

ASP 8825 Phase II Study-A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy

To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.

Three doses of ASP8825 are compared to placebo in efficacy and safety point of view in patients with painful diabetic polyneuropathy.

Inclusion Criteria:

• Subjects aged 20 - 79 years
• Diabetes mellitus patients with diabetic polyneuropathy who have pain symptom for 26 weeks prior to the study
• Subjects who are compliant with diary completion

Exclusion Criteria:

• Subjects who have pain from other diseases at the evaluating site
• Subjects who have nerve diseases at the evaluating site
• Subjects with foot ulcer or gangrene